SigSino Therapeutics Secures Second Place in the 8th Guangming Innovation and Entrepreneurship Competition with AI-Driven Organoid Platform for Oncology Drug Discovery

Recently,The 8th Guangming District Innovation and Entrepreneurship CompetitionThe final came to a successful conclusion after the preliminary, semi-final, and final rounds of intense competition and selection.SIGNET's "AI Tumor Targeted Drug Development Based on Organoids" project ultimately stood out from 1,040 projects across all industries, securing second place in the biomedicine industry finals and winning a prize of 80,000 yuan.。

The 8th Guangming District Innovation and Entrepreneurship Competition is guided by Shenzhen Municipal Science and Technology Innovation Bureau and the People's Government of Guangming District, Shenzhen, hosted by the Science and Technology Innovation Bureau of Guangming District, Shenzhen, and organized by Shenzhen Industry-University-Research Cooperation Promotion Association. In addition to receiving cash prizes, the winning projects will also receive relevant government policy support. For each level advanced in national or municipal competitions, they will receive corresponding support from Shenzhen (national competition, municipal competition prize money, and entrepreneurship funding).

SIGNET isThe First Innovative Targeted Drug Development Company in China Based on Organoids + AICurrently, the first pipeline SIGX1094 developed by the company based on this platform has entered Phase I clinical trials in just over three years, obtaining IND approval from China's NMPA and the U.S. FDA, and recently receiving Orphan Drug Designation from the U.S. FDA.

The organoid disease models of Signet Therapeutics can accurately simulate the growth characteristics of patient tumors and their response to drugs. Combined with AI-powered efficient data analysis, the team is able to precisely screen potential drug targets, optimize drug design, and conduct efficacy evaluations, addressing issues that may arise in the clinical stage during the preclinical phase. This greatly enhances the efficiency and success rate of drug development.

This award reflects the high recognition from the expert jury and the government of SIGNET's scientific research strength and innovative achievements. SIGNET will continue to adhere to its original R&D mission, committing to promoting source innovation in China's biopharmaceutical field and contributing to the industry's development.

Signet Therapeutics is the first company in China to develop innovative targeted cancer drugs based on organoid disease models and AI. It was initially founded on the Harvard University campus and established in Shenzhen by the end of 2020, completing financing and project funding totaling nearly 220 million yuan. Signet is not only a transliteration of "Signet," but also adheres to the vision of “Hopeful Hearts, Studying Things to Gain Knowledge.” By leveraging the critical role of organoid disease models that closely resemble patient genomic characteristics in drug efficacy evaluation and new target discovery, combined with AI-powered screening, synthesis, and optimization of small molecule compounds, it develops first-in-class innovative targeted drugs. The company currently has four drug pipelines, with the lead pipeline developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer, which has now entered Phase I clinical trials. The company has a 1,200-square-meter R&D facility and a 500-square-meter experimental animal housing area. Signet Therapeutics' disease model platform not only serves its own drug pipelines but also actively empowers large pharmaceutical companies in new drug development. Its collaborative partners include Shenzhen BioRay Pharmaceutical, Truebio, and others, contributing to the birth of more innovative drugs.